Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo - Seite 2

Rahul Aggarwal, Deepak L. Bhatt, Philippe Gabriel Steg, Michael Miller, et al.
-Available Apil 6^th, 12:15-12:25 PM
-Moderated Poster Theater 08

• Eicosapentaenoic Acid (EPA) Inhibits Lipoprotein(a) [Lp(a)] Oxidation due to Scavenging Mechanisms in Vitro
  Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al.
  -Available April 7^th, 9:30-9:40 AM
  -Moderated Poster Theater 06

Poster Presentations

• Eicosapentaenoic Acid (EPA) and a High Intensity Statin Enhanced Expression of Proteins for Detoxification of Reactive Oxygen Species During Angiotensin II Challenge in Endothelial Cells
  Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al.
  -Available April 7^th, 1:15-2:00 PM
  -Hall B4-5

• Eicosapentaenoic Acid and Rosuvastatin Modulate Expression of Endothelial Proteins that Regulate Function and Platelet Activity During Angiotensin II Stimulation
  Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al.
  -Available April 7^th, 1:15-2:00 PM
  -Hall B4-5

• Effects of Icosapent Ethyl on Vascular Regenerative Cells in Individuals with Elevated Triglycerides: Insights From the IPE-Prevention Cardiolink-14 Trial
  Ehab Bakbak, Aishwarya Krishnaraj, Deepak L. Bhatt, Brady Park, et al.
  –Available April 8^th, 12:45-1:30 PM
  - Hall B4-5

About Amarin 
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.  

About Cardiovascular Risk
Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.¹  And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.